No breast cancer subgroup can be spared postoperative radiotherapy after breast-conserving surgery. Fifteen-year results from the Swedish Breast Cancer Group randomised trial, SweBCG 91 RT.

BACKGROUND Breast-conserving surgery (BCS) followed by radiotherapy (RT) is an established treatment for women with T1-2N0 breast cancers. Since subgroups of patients have low ipsilateral breast tumour recurrence (IBTR) rates, it is important to study whether RT is necessary for all patients. PATIENTS AND METHODS A total of 1187 women with primary T1-2N0M0 breast cancer were randomised, after standardised sector resection, to postoperative whole breast RT or no local treatment. Adjuvant systemic therapy was offered to patients with stage II cancers. Patients were followed with clinical examinations and annual mammography for 10 years and thereafter referred to the Swedish mammography screening program. RESULTS After 15 years of follow-up, a higher cumulative incidence of IBTR was observed in control patients, 23.9%, versus irradiated patients, 11.5%, P<0.001. Recurrence-free survival was inferior, 51.7% versus 60.4%, P=0.0013. The main effect of RT was seen during the first 5 years. However, overall survival was not significantly lower 68.4% versus 71.1%, P=0.68, nor was breast cancer-specific mortality significantly higher. CONCLUSIONS RT after BCS significantly reduced the incidence of IBTR at 15 years of follow-up. We were unable to identify subgroups which could be spared RT. Breast cancer mortality was not significantly reduced after RT. Good predictive markers for radiation sensitivity and improved adjuvant systemic therapy are needed to omit RT after BCS.

[1]  Carsten Peterson,et al.  Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy , 2008, Breast Cancer Research.

[2]  L. Tabár,et al.  10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Pötter,et al.  Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. , 2005, International journal of radiation oncology, biology, physics.

[4]  J. Costantino,et al.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. Holmberg,et al.  Standardization of the surgical technique in breast‐conserving treatment of mammary cancer , 1988, The British journal of surgery.

[6]  Christian Carrie,et al.  Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. , 1997 .

[7]  R. Gelber,et al.  Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. , 2014, The Lancet. Oncology.

[8]  F. Vicini,et al.  Molecular evidence demonstrating local treatment failure is the source of distant metastases in some patients treated for breast cancer. , 2008, International journal of radiation oncology, biology, physics.

[9]  G. Steineck,et al.  Symptoms 10-17 years after breast cancer radiotherapy data from the randomised SWEBCG91-RT trial. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  Barbara L. Smith,et al.  Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Duffy,et al.  Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. , 2013, European journal of cancer.

[12]  B. E. F. Isher,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .

[13]  Umberto Veronesi,et al.  Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. , 2002, The New England journal of medicine.

[14]  Emmanuel Barillot,et al.  High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. , 2008, Journal of the National Cancer Institute.

[15]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Melania Pintilie,et al.  Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. , 2004, The New England journal of medicine.

[17]  Norman Wolmark,et al.  Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Emmanuel Barillot,et al.  Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women , 2012, Clinical Cancer Research.

[19]  M. Ringnér,et al.  Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs , 2008, BMC clinical pathology.

[20]  L. Holmberg,et al.  Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening. , 2003, European journal of cancer.

[21]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[22]  D. Cameron,et al.  Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. , 2015, The Lancet. Oncology.

[23]  J. Yarnold,et al.  Ipsilateral breast tumor relapse: local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primaries. , 2011, International journal of radiation oncology, biology, physics.

[24]  S. Schnitt,et al.  A prospective study of conservative surgery alone in the treatment of selected patients with stage I breast cancer , 1996, Cancer.

[25]  R Peto,et al.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials , 2011, The Lancet.

[26]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[27]  E Marubini,et al.  Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Barbara L. Smith,et al.  Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. , 2004, The New England journal of medicine.

[29]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Laurence Collette,et al.  Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial , 2007 .

[31]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[32]  G. Steineck,et al.  Risk factors of developing long-lasting breast pain after breast cancer radiotherapy. , 2012, International journal of radiation oncology, biology, physics.

[33]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[34]  S. Jolly,et al.  Long-Term Patterns of In-Breast Failure in Patients With Early Stage Breast Cancer Treated With Breast-Conserving Therapy: A Molecular Based Clonality Evaluation , 2010, American journal of clinical oncology.

[35]  Howard Y. Chang,et al.  Predicting a local recurrence after breast-conserving therapy by gene expression profiling , 2006, Breast Cancer Research.

[36]  S. Paik,et al.  Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. O'toole,et al.  Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Frigessi,et al.  Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort , 2014, Clinical Cancer Research.